leisure time -WSS

leisure time

author：leisure time 2025-09-14 10:02:38 - browse：6

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Ebola public health emergency is over, WHO declares

focus

WSS

Celebrate National Dole Whip Day for 3 days this week at Disney

The kidney, in all its complexity, is captured in a new atlas

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

How dance can help health care workers heal from trauma

Seattle police shoot person suspected in downtown stabbing

Stanford updates investigation of president’s past research

explore

leisure time

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

DOJ, FTC to increase scrutiny of all types of health care mergers

Anesthesiologist group: stop taking Ozempic before surgery

Class action alleges UnitedHealth concealed DOJ probe

Apple is now the first public company to be valued at $3 trillion

GSK’s asthma push continues as drug succeeds in Phase 3 trials

What does generative AI mean for health care? We asked experts

Plane’s emergency slide plummets from sky, hits Chicago home

George Santos makes 1st court appearance after pleading not guilty to 13 counts

PBM executives asked to testify by House panel

hotspot

AI for drug discovery: Experts on separating hype from reality

Is it ever OK for doctors to lie to their patients?

Seattle police shoot person suspected in downtown stabbing

'Reaching a detente': STAT's Helen Branswell on covering Covid

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Couple fighting to bring baby home from Mexico are finally reunited

entertainment

focus

focus

Wikipedia